Approximately half of men with metastatic castration-resistant prostate cancer and BRCA1 or BRCA2 mutations do not receive medications that could improve their survival.Poly (adenosine ...
Once E3 tags CYP17A1, the cell uses its proteasome to break down the enzyme entirely. One major advantage of PROTACs is that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback